Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

(2016) S. Pospisilova et al.   HAEMATOLOGICA

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

(2016) S. Pospisilova et al.   HAEMATOLOGICA

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

(2015) H. S. Walter et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

(2015) A. Wiestner   HAEMATOLOGICA

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

(2015) A C Rawstron et al.   LEUKEMIA

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

(2015) Valentin Goede et al.   LEUKEMIA & LYMPHOMA

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

Targets for Ibrutinib Beyond B Cell Malignancies

(2015) A. Berglöf et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

(2015) A. Wiestner   HAEMATOLOGICA

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Schistosomal eggs identified on bone marrow biopsy

(2014) C. Jones et al.   BLOOD

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

(2013) Amin Aalipour et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry

(2013) E. A. Femia et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

(2013) Jennifer R. Brown   LEUKEMIA & LYMPHOMA

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials

(2013) Jennifer R. Brown   Current Hematologic Malignancy Reports

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

(2012) Adrian Wiestner   JOURNAL OF CLINICAL ONCOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

(2012) Petra Jilma-Stohlawetz et al.   THROMBOSIS AND HAEMOSTASIS

Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration

(2011) Alexander Spiel et al.   THROMBOSIS AND HAEMOSTASIS